Work

Supplementary Figure 4 from The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib

Year: 2023

Type: supplementary-materials

Abstract: Antitumor activity and toxicity of the indenoisoquinolines LMP400, LMP744 and LMP776 in Brca1-deficient murine orthotopic allograft model for ovarian cancer and synergy of LMP400 with olaparib. A-C. Antitumor activity of LMP400, LMP744, LMP776, olaparib alone and olaparib combination with LMP400 represented as tumor volume changes in individual mice. Single treatment experiment (A) and Combination study (C). B-D. Mice Body Weight changes for the corresponding experiments. Single treatment experiment (B) and Combination study (D).

DOI: 10.1158/1078-0432.22471655

Authors: Laetitia Marzi, Ludmila Szabova, Melanie Gordon, Zoe Weaver Ohler, Shyam K. Sharan, Michael L. Beshiri, Moudjib Etemadi, Junko Murai, Kathleen Kelly, Yves Pommier

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362407141

Cites:

Cited by:

Related to: 10